Deutsche Bank Aktiengesellschaft reaffirmed their hold rating on shares of GSK (LON:GSK – Get Rating) in a research note published on Wednesday, Marketbeat Ratings reports. They currently have a GBX 1,500 ($18.04) target price on the stock.
A number of other brokerages have also weighed in on GSK. Shore Capital restated a buy rating on shares of GSK in a research note on Friday, February 24th. UBS Group set a GBX 1,245 ($14.97) target price on shares of GSK in a research report on Wednesday, February 1st. Citigroup decreased their price target on shares of GSK from GBX 1,975 ($23.75) to GBX 1,550 ($18.64) and set a neutral rating for the company in a report on Friday, December 2nd. Berenberg Bank set a GBX 1,730 ($20.80) price objective on shares of GSK in a report on Friday, February 10th. Finally, JPMorgan Chase & Co. set a GBX 1,400 ($16.84) target price on GSK in a research report on Thursday, March 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of Hold and a consensus price target of GBX 1,551.11 ($18.65).
GSK Stock Performance
Shares of GSK stock opened at GBX 1,421.20 ($17.09) on Wednesday. GSK has a 12-month low of GBX 1,280.92 ($15.40) and a 12-month high of GBX 2,280.50 ($27.42). The business’s fifty day simple moving average is GBX 1,440.85 and its 200-day simple moving average is GBX 1,404.05. The company has a current ratio of 0.91, a quick ratio of 0.73 and a debt-to-equity ratio of 207.87. The company has a market cap of £58.13 billion, a PE ratio of 1,304.95, a PEG ratio of 1.14 and a beta of 0.27.
GSK Dividend Announcement
Insider Buying and Selling at GSK
In related news, insider Urs Rohner acquired 798 shares of GSK stock in a transaction on Thursday, December 22nd. The stock was acquired at an average price of GBX 1,453 ($17.47) per share, for a total transaction of £11,594.94 ($13,942.93). In other news, insider Jonathan Symonds bought 2,100 shares of the firm’s stock in a transaction that occurred on Tuesday, December 20th. The stock was purchased at an average cost of GBX 1,417 ($17.04) per share, for a total transaction of £29,757 ($35,782.83). Also, insider Urs Rohner purchased 798 shares of the stock in a transaction that occurred on Thursday, December 22nd. The shares were purchased at an average cost of GBX 1,453 ($17.47) per share, for a total transaction of £11,594.94 ($13,942.93). Over the last three months, insiders have acquired 2,915 shares of company stock valued at $4,160,059. 0.72% of the stock is owned by insiders.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey’s General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.